Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01012687 · ClinicalTrials.gov registry record · NA
Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fasted Conditions
A NA study of Essential Hypertension, sponsored by Roxane Laboratories.
- Completed
- Registry status
- NA
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT01012687: Completed NA study of Essential Hypertension, sponsored by Roxane Laboratories.
NCT01012687 is a NA study of Essential Hypertension that has completed, run by Roxane Laboratories. The registered enrollment target is 48 participants, below the 798-participant average among 8 other Essential Hypertension trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01012687, a NA study of Essential Hypertension, has completed, sponsored by Roxane Laboratories.
- COMPLETED
- Registry status
- NA
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study was to prove the bioequivalence of Perindopril Erbumine 8 mg tablets under fasting conditions.
Conditions Studied
Interventions
- DRUG perindopril erbumine
Study Locations (1)
Texas
- Novum Pharmaceutical Research Services - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2007-04 |
| Est. Completion | 2007-05 |
| Phase | NA |
What the finished NCT01012687 record still lists
NCT01012687 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 798-participant average among 8 other Essential Hypertension trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Essential Hypertension appearing as the primary indexed condition, and to 1 intervention - of which perindopril erbumine is the first listed.
NCT01012687 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT01012687 about?
NCT01012687 is a clinical study titled "Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fasted Conditions". The objective of this study was to prove the bioequivalence of Perindopril Erbumine 8 mg tablets under fasting conditions.
What is the current status of trial NCT01012687?
This trial is currently completed. It is a NA study. The enrollment target is 48 participants. The study started on 2007-04. Estimated completion is 2007-05.
What conditions does trial NCT01012687 study?
This clinical trial studies the following conditions: Essential Hypertension.
What interventions are being tested in trial NCT01012687?
The interventions under investigation include: perindopril erbumine (DRUG).
Who is sponsoring clinical trial NCT01012687?
This trial is sponsored by Roxane Laboratories, which has 93 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01012687 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Essential Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01012687's enrollment target sits among peer trials
48 8th of 8 higher than 1 of 8 other Essential Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Essential Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Childhood-Onset Essential Hypertension Natural History Study
RECRUITING
-
Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension
ACTIVE NOT RECRUITING
-
Uric Acid in Essential Hypertension in Children
COMPLETED · Phase 2
-
Hypertension: Prediction of Biofeedback Success
COMPLETED · Phase 1
-
A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension
COMPLETED · Phase 3
-
Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia